Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

250
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
250
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

425
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
425
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

569
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
569
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

456
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
456
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

302
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
302
Pneumonia IV: Management01:28

Pneumonia IV: Management

531
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
531

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea.

Naunyn-Schmiedeberg's archives of pharmacology·2023
Same author

Dapsone Lowers Neutrophil to Lymphocyte Ratio and Mortality in COVID-19 Patients Admitted to the ICU.

International journal of molecular sciences·2022
Same author

COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs.

International journal of molecular sciences·2022
Same author

Dapsone is an anticatalysis for Alzheimer's disease exacerbation.

iScience·2022
Same author

Correction to: The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.

Naunyn-Schmiedeberg's archives of pharmacology·2022
Same author

Benefits of Using Dapsone in Patients Hospitalized with COVID-19.

Vaccines·2022

Related Experiment Video

Updated: Oct 30, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.9K

Specific Treatment Exists for SARS-CoV-2 ARDS.

Badar Kanwar1, Chul Joong Lee2, Jong-Hoon Lee3

  • 1Department of Pulmonary Critical Care Medicine, Hunt Regional Hospital, Greenville, TX 75401, USA.

Vaccines
|July 2, 2021
PubMed
Summary

Dapsone may reduce severe acute respiratory distress syndrome (ARDS) and mortality in COVID-19 patients. This leprosy medication showed promise in treating SARS-CoV-2 infections, potentially by affecting brainstem responses.

Keywords:
brainsteminflammasomeoral DNA vaccine

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K
Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.6K

Related Experiment Videos

Last Updated: Oct 30, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

2.9K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.0K
Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS
06:22

Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome ARDS

Published on: April 7, 2021

3.6K

Area of Science:

  • Neurology
  • Infectious Diseases
  • Pharmacology

Background:

  • COVID-19, caused by SARS-CoV-2, presents with respiratory and neurological symptoms.
  • Neurological manifestations and sequelae of COVID-19 are increasingly recognized.
  • A case series noted rapid recovery from ARDS within 24 hours in COVID-19 patients with neurological disease.

Purpose of the Study:

  • To investigate the potential of dapsone in treating COVID-19 associated ARDS.
  • To compare mortality rates in COVID-19 patients with and without dapsone treatment.
  • To explore the relationship between dapsone, neuroinflammation, and neurological outcomes in SARS-CoV-2 infection.

Main Methods:

  • A preliminary cross-sectional study compared COVID-19 patients receiving dapsone with a control group.
  • Analysis of mortality rates at the ARDS onset stage.
  • Review of dapsone's effects on human neuroinflammation, drawing parallels with SARS-CoV-2.
  • Observation of leprosy patients on Sorok Island, South Korea, with low AD prevalence.

Main Results:

  • Mortality rates at ARDS onset were 0% with dapsone versus 40% without.
  • A statistically significant result (p < 0.05) was observed in a trial group of 22 subjects and a control group of 22 subjects.
  • Dapsone demonstrated different effects in the brain compared to SARS-CoV-2.
  • Low Alzheimer's disease prevalence was noted in leprosy patients regularly taking dapsone.

Conclusions:

  • Dapsone may significantly reduce the incidence of ARDS and other SARS-CoV-2 related illnesses.
  • Dapsone's potential therapeutic role in managing severe COVID-19, particularly neurological and respiratory complications, is suggested.
  • Further research is warranted to elucidate dapsone's mechanisms in treating COVID-19 ARDS.